Arbutus Announces Presentations at HepDART 2017
28 November 2017 - 1:00AM
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced two oral presentations and one poster presentation at
HepDART 2017 being held on December 3 - 7, 2017 in Kona, Hawaii.
Presentations Include:
Oral Presentation: “Controlling HBsAg as a Key
Component of a Combination Strategy to Affect an HBV Cure” by
Michael J. Sofia, Chief Scientific Officer
- December 5, 2017, 6:50pm - 7:10pm (HST), Shifting the Tide of
Drug Development Towards HBV, NASH, and HCC: Battling Giant
KillersSummary: HBV produces significant quantities of surface
antigen (HBsAg)-containing subviral particles, which is believed to
play a major role in the immune exhaustion observed in chronic HBV
patients, suggesting that reducing or eliminating HBsAg may be
critical for developing a curative regimen. An update will be
presented on HBsAg reducing strategies for HBV treatment that
include lipid nanoparticle (LNP) siRNAs and small molecule RNA
destabilizers. In addition, in vitro and in vivo combination
studies of HBsAg reducing agents with other mechanism of action
agents will be described.
Oral and Poster Presentation #8: “A Next
Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo
Antiviral Characterization” by Nagraj Mani, Senior Principal
Scientist
- December 5, 2017, 3:30pm - 5:00pm (HST), Poster Session
- December 6, 2017, 12:00pm - 12:10pm (HST), Oral Abstract
Session IVSummary: Arbutus’ next-generation, highly selective HBV
capsid inhibitor AB-506, has the potential to be a best-in-class
capsid inhibitor based on its favorable drug-like properties and
potent inhibition of HBV replication both in vitro and in vivo. In
a HBV cell culture model, AB-506 treatment resulted in empty capsid
formation devoid of the viral genome. AB-506’s improved potency is
a result of improved binding interaction with the core protein and
represents enhanced target engagement compared to earlier capsid
inhibitors. This molecule has the potential for once daily oral
dosing and is expected to be the subject of a regulatory filing in
mid-2018.
These presentations will be available by
visiting the Investor section of www.arbutusbio.com and selecting
Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a
biopharmaceutical company dedicated to discovering, developing and
commercializing a cure for patients suffering from chronic HBV
infection. Arbutus is headquartered in Vancouver, BC, and has
facilities in Warminster, PA. For more information, visit
www.arbutusbio.com.
Contact Information
InvestorsBruce CousinsExecutive Vice President
and Chief Financial OfficerPhone: 604-419-3200Email:
bcousins@arbutusbio.com
Tiffany TolmieManager, Investor RelationsPhone: 604-419-3200
Email: ttolmie@arbutusbio.com
MediaDavid SchullRusso PartnersPhone:
858-717-2310Email: david.schull@russopartnersllc.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2024 to May 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From May 2023 to May 2024